Introduction
Many prostate cancers are unlikely to cause harm during a man's lifetime and can be safely managed conservatively, with active surveillance (AS) or watchful waiting (WW). AS involves serial testing (e.g. PSA, DRE, biopsy) to monitor for disease reclassification over time and offer selective curative intervention, whereas, WW is a less intensive observation approach without curative intent. Recent data from the US CaPSURE registry showed increasing use of AS/WW, with its use in 40.4% of low-risk cases and in 76.2% of men aged ≥75 years in 2010-2013 [1] . Despite similar increasing global trends [2, 3] , there remains no consensus regarding patient selection and follow-up protocols, with multiple divergent published protocols and guidelines [4] [5] [6] [7] [8] .
Several small quantitative surveys have examined this heterogeneity in AS practice [9] . Gorin et al. [10] reported a survey of 387 urologists primarily based in the USA. While 94% and 74% of respondents agreed that eligibility should be limited to men with PSA levels ≤10 ng/mL and Gleason scores ≤6, respectively, there was no consensus regarding the timing of follow-up biopsies and use of PSA kinetics.
A 2012-2013 survey of 35 British physicians found general consensus that patients with Gleason score 6, stage ≤T2 cancer, and PSA levels ≤10 ng/mL are suitable for AS [11] ; however, there was less consensus about the suitability of intermediate-risk patients for AS, and regarding the use of age and MRI in candidate selection. There was also significant heterogeneity between respondents in the frequency of PSA testing, use of DRE, and timing of repeat biopsies.
The aim of the present study was to examine the motivations behind physician decision-making in relation to AS monitoring practices, given that there is no internationally accepted standard. Qualitative methods are particularly valuable for understanding phenomena from the perspective of study participants and to uncover the beliefs, values and motivations behind individual behaviour [12] . Identifying which factors influence physicians' decisions during AS is an important first step to understanding how we can improve surveillance.
Subjects and Methods
From July to December 2015, we conducted semi-structured, indepth interviews with prostate cancer physicians. First we purposively sampled urologists from the AUA to obtain detailed perspectives from experts in the field, including geographically diverse settings across the USA [13] . Purposive sampling is a non-probability sampling technique used to ascertain information about a specific population [13] . A snowball recruitment strategy was used, in which initial informants could then nominate other potential participants through connections in the field, including providers with different expertise involved in the care of patients on active surveillance [14] .
Physicians were eligible if they reported currently caring for patients undergoing AS in the USA. We sent email invitations to a total of 48 physicians and conducted 24 interviews until we reached thematic saturation, wherein the research team reached consensus that no new themes were emerging from the interviews and therefore no further interviews were necessary [15, 16] .
The study was approved by the institutional review board. Prior to the interview, all participants provided written informed consent and completed intake questionnaires with demographic information and criteria for patient selection and monitoring during AS.
Interviews
Qualitative interviews formed the primary data collection for our study. The research team developed an interview guide based on a literature review and previous research on AS [17] [18] [19] [20] . We tested the guide with two pilot interviews and then modified it to improve clarity. Interview questions focused on specific protocols for monitoring during AS, how physicians chose the frequency of follow-up tests, opinions about testing options, and comfort with AS (Appendix S1). S.L. and E.S. conducted interviews in-person or by telephone, which lasted a mean (range) of 36 (22-51) min.
Analysis
Responses to intake questionnaires were recorded in the secure Research Electronic Data Capture (REDCap) portal, and descriptive statistics were used to aggregate the results. We audio-recorded all interviews and focus groups, and a third-party service anonymously transcribed them. Transcripts were entered into NVIVO10 qualitative software for data management and retrieval [21, 22] .
We analysed transcripts using Applied Thematic Analysis, an inductive set of procedures designed to identify and examine emerging themes from conceptual data [23] . Two researchers independently reviewed transcripts to develop an initial codebook and coded each transcript, modified the codebooks as themes emerged, and met to discuss and reconcile discrepancies until a final coded transcript was agreed upon. The team resolved disagreements around codes, themes, and subthemes by discussion or by going back to the original transcripts. Finally, themes from interviews and focus groups were organized using descriptive matrix analyses that visually displayed the range of responses related to each theme. Table 1 shows the demographics of the study population. The majority of participants were urologists (83%), with a primary expertise of prostate cancer or urological oncology (83%). The participants practised in a variety of settings across 11 states. Physicians reported a variety of factors that affected how they monitored patients on AS and their comfort with current monitoring practices. Eight key themes were identified to explain the variability in AS protocols (Fig. 1 ), which are further described with quotes.
Results

Physician Comfort with Active Surveillance
All participants stated that among the biggest advances in AS was the availability of long-term outcomes data, which made them more comfortable recommending AS. All physicians agreed that AS is now a standard management approach and not experimental. 
Protocol Selection
Despite agreement that AS is now a standard option, we found wide variability in methods used to monitor patients on AS in the pre-interview questionnaires (Table 2) . For patient selection, there was 100% agreement on grade, and nearly all participants also used PSA and clinical stage. There was less agreement on the use of age, imaging and other tests for patient selection or monitoring.
Variation in AS practices was also reflected during interviews. For example, several physicians reported following one published protocol strictly; whereas, other participants felt that since there were no empiric data showing the superiority of any one strategy, follow-up should be tailored to individual patient preferences, physician discretion and experience. 
Beliefs about the Utility and Quality of Testing
There was a wide range of responses about the utility and quality of specific tests (Table 3) . Some physicians believed a particular test was the 'gold standard', while others felt it was 'useless'. All physicians stated that they rely heavily on biopsy results and most felt PSA was less important.
'Most of the studies show that PSA is not a reliable trigger for intervention. And so we get it but then we don't know what to do with it, and it just ends up scaring patients.' [Physician 3] Responses about marker tests varied considerably; most physicians stated that they were still novel and expressed uncertainty if the benefit justified the cost. 'I don't have access to any of those [marker tests], so I don't have any experience in using them.' [Physician 23] 'I haven't really started to use any of the more sophisticated genetic markers yet. I think the jury is still out on some of those like OncotypeDX and Prolaris, etc. I did use PCA3 for a while but I haven't found it to be tremendously helpful in most cases.' [Physician 3] Most physicians felt that MRI was useful to reduce the number of biopsies, but that high-quality results were not available in all settings.
'I think MRI has been very helpful in determining who might be a candidate for AS if either prior to the first biopsy in some cases or subsequent to the biopsy to ensure that there is not a large tumour that was missed.' [Physician 3]
Years of Experience and Exposure to Active Surveillance During Training
Physicians' feelings regarding AS varied depending on how long ago they trained. Physicians who completed training recently tended to follow specific protocols more strictly (e.g. Klotz or Johns Hopkins), and several reported being uncomfortable with the lack of national guidelines. Lastly, a few physicians mentioned that AS was not as prioritized as 'treatment' during residency, so they did not feel properly trained to care for men on AS. Several participants mentioned emulating former mentors' AS protocols in lieu of formal training.
'We train people to do something, we pay to do something. We are by nature doers and AS is not really Nearly all participants mentioned the tension between 'over-' or 'under-' testing patients and the desire to reduce 'harm' whether through repeat biopsies vs the risk of 'missing' aggressive disease.
'I think we still don't understand the impact of repetitive biopsies with inflammation and infection risks. Especially for the ones that we start surveillance young.' [Physician 2] 'It's been placed in your hands to treat their prostate cancer, and it's possible that you miss the window of curability on your watch. They could be hurt by that choice. That's a lot of responsibility.' [Physician 1]
Several participants mentioned medico-legal concerns. Some mentioned that AS places liability on the physician, and felt the need to 'cover' themselves.
Main themes elicited from physician interviews
Beliefs about and comfort with AS
o The publication of several long-term cohort studies exhibiting a low risk of mortality for patients on AS has made providers more comfortable with this management strategy.
Protocol selection differs among physicians
o Physicians are aware of published AS guidelines and protocols but often rely their own intuition when deciding on follow-up testing.
Beliefs about the utility and quality of testing
o Physicians had a wide range of opinions on the usefulness of certain tests for monitoring patients on AS, particularly PSA, marker tests, and MRI.
Physician years of experience and exposure to AS during training
o Older physicians expressed a greater comfort with managing patients on AS.
Physicians reported greater emphasis on procedural skills and less exposure to AS during training.
Concerns about the risk of inflicting "harm"
o Physicians expressed concerns about the possibility of performing too many invasive tests versus not following a patient closely enough and missing disease progression.
Patient characteristics
o Physicians consider a number of patient characteristics such as age, comorbidities, and history of compliance for AS eligibility.
Patient preferences
o Shared decision making was commonly mentioned by physicians. Patient preferences are often taken into consideration when deciding which follow-up tests to perform and how frequently to perform them.
Financial incentives
o Physicians felt that financial incentives do not influence their individual AS monitoring practices but that the U.S. healthcare system affects physician's decision to recommend AS initially. 
Patient Characteristics
Most physicians consider patient characteristics such as age, comorbidities, and history of compliance when deciding who is an appropriate candidate for AS and when it should be discontinued.
'You know, you look at age and comorbidities. I don't think any of us put guys under 50 on surveillance and some of my colleagues are a little reluctant to put anybody under 60 on surveillance.' [Physician 12]
'I follow people pretty carefully because I also think that them seeing me frequently decreases the likelihood that they're going to be lost to follow-up.' [Physician 23]
Physicians also reported considering patients' financial and insurance status before recommending certain tests.
'I think one of the limitations of using something like the 4KScore is that it's so expensive and it's not reimbursed. Finally, some physicians reported a lack of guidance regarding decisions to transition from AS to WW, and that this decision was individualized based on patient characteristics. 
Financial Incentives
Physicians did not believe that financial incentives directly affected their individual practice or their decisions while monitoring men on AS, but many acknowledged that it is a part of the healthcare industry in the USA and may influence a physician's decision to recommend AS upfront. Some physicians felt that financial incentives were a reason why the uptake of AS in the US has been slower than in other countries.
'Guys in practice make their money doing things. They don't make nearly as much money doing surveillance and I think that that plays a lot into it. I think there is this attitude that I have heard expressed many times which is, you know, I believe in surveillance, you watch the tumour all the way to the time you wheel the patient in the operating room. 
Discussion
There is significant heterogeneity in the real-world practice of AS, consistent with previous quantitative studies [10, 11, 24] . Using qualitative methods, we explored the reasons for variability in AS and factors influencing the physician decision-making process. Eight key themes emerged: (i) physician comfort with AS; (ii) protocol selection; (iii) beliefs about the utility and quality of testing; (iv) years of experience and exposure to AS during training; (v) concerns about inflicting 'harm'; (vi) patient characteristics; (vii) patient preferences; and (viii) financial incentives.
Although physician comfort with AS has increased and it is now considered a standard management option, there are substantial differences in protocol selection. In particular, our results illustrate the conflict between guideline-based vs personalized medicine [25] . While standardized, evidence-based care is generally considered 'best practice', it is important to note that there are multiple published protocols for monitoring during AS. For example, the frequency of follow-up biopsy varies between programmes and new tests such as MRI are starting to become integrated, but there is a lack of prospective data comparing the long-term outcomes among these differing approaches [26] .
Indeed, the question of whether it is appropriate to use the same protocol for vastly different patient populations has not been answered. For example, some factors that emerged in the present study as key themes for decisionmaking (age and comorbidity) also significantly impact the risk-to-benefit ratio of intense monitoring (biopsy risks, risk-to-benefit of undergoing definitive treatment for localized disease), and therefore heterogeneity based on these factors may be justifiable or even preferred [27, 28] . Furthermore, the risk of disease reclassification is a conditional probability, whereby the risk is reduced with each negative surveillance biopsy [29] . Tailoring AS protocols over time, therefore, based on updated results may be optimal. Although many new tests are available that could be used to tailor AS, such as MRI and genomic tests, the uptake and perceptions of these tests remained variable among participants. Table 4 summarizes key actionable recommendations and research gaps identified through our study. First is the lack of randomized data comparing different AS protocols or alternative testing strategies. This was previously identified as an important research gap by a 2011 National Institutes of Health (NIH) consensus conference [30] , and our findings confirm the ongoing need for additional data to help inform and standardize clinical practice. Notably, an ongoing prospective study in Sweden is comparing two different AS approaches [31] . Furthermore, in the absence of randomized comparison studies, modelling studies would be useful to compare benefits, harms and costs of different protocols.
Another novel finding of the present study is the lack of emphasis on AS during urology training, with greater emphasis placed on procedural skills. This is an important and actionable finding, suggesting the need to make AS a core part of urology training and continuing medical education.
A limitation of this study is that physicians who chose to participate may differ from other physicians, which could produce a selection bias. Although our gender distribution was in line with national estimates (~8% of US urologists are women [32] ) and we included providers from a variety of practice settings, our study population was younger (mean age 43 years) than the national average (more than half of practising urologists aged >53 years) [33] . Although purposive sampling was used to increase diversity across geographic areas and specialties, only US physicians were included and AS practices may differ in other healthcare systems and cultures, and our study did not include any primary care providers. Lastly, although physicians were asked about concerns expressed by their patients, actual patient perspectives were not included in the present analysis and will be the subject of future study. As is the goal of qualitative research, this study was designed to engender deeper knowledge in a specific context, rather than generalizable findings.
In conclusion, physician, patient and healthcare system factors all contribute to the underlying heterogeneity in AS practices in the USA. More data are needed comparing the benefits, harms and costs of alternative protocols to inform a more standardized approach, and greater emphasis is needed on managing patients who are undergoing AS during urology training and continuing education.
